Zaman Shah, MD
Internal Medicine · Sheffield, ALNPI 1588972673
Payments from drug & device makers
Across 77 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$583
- Merck$225
- AstraZeneca$215
- Novo Nordisk$155
- AbbVie$82
- Verona Pharma, Inc.$52
- plus $231 from 11 others
What the payments were for
- Food & beverage$1,543100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 29 | $583 |
| Merck | 9 | $225 |
| AstraZeneca | 8 | $215 |
| Novo Nordisk | 10 | $155 |
| AbbVie(2 entities) | 5 | $82 |
| Verona Pharma, Inc. | 2 | $52 |
| Lilly USA, LLC | 2 | $36 |
| Astellas Pharma US Inc | 2 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Pfizer | 1 | $21 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| Insulet Corporation | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Novartis | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$110
- AREXVY$107
- BREZTRI AEROSPHERE$101
How this compares
$1,543 in reported general payments places this provider in the 65th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 64 | $86,058 |
| EliquisApixaban | 74 | $79,810 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $67,769 |
| FarxigaDapagliflozin Propanediol | 63 | $62,869 |
| TrulicityDulaglutide | 33 | $43,063 |
| JanuviaSitagliptin Phosphate | 23 | $27,288 |
| OzempicSemaglutide | 15 | $22,172 |
| LinzessLinaclotide | 19 | $17,695 |
| XareltoRivaroxaban | 14 | $15,763 |
| JardianceEmpagliflozin | 11 | $14,675 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $12,878 |
| EntrestoSacubitril/Valsartan | 13 | $12,408 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $7,644 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 357 | $7,310 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,755 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $36 | $129,12197 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $215 | $83,39198 claims |
| PfizerEliquis | $21 | $79,81074 claims |
| GSKTrelegy Ellipta | $583 | $67,76962 claims |
| MerckJanuvia | $225 | $27,28823 claims |
| Novo NordiskOzempic | $155 | $22,17215 claims |
| AbbVieLinzess | $82 | $17,69519 claims |
| Boehringer IngelheimJardiance | $34 | $14,67511 claims |
| NovartisEntresto | $12 | $12,40813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Sheffield
- Faizullah SyedSheffield$397K
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.